Zigao Yuan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Zigao Yuan has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Yuyang Jiang
Guangdong Provincial Key Laboratory of Chinese Medicine Ingredients and Gut Microbiomics, School of Pharmacy, Shenzhen University Medical School
11 shared publications Chunmei Gao
7 shared publicationsQiuzi Dai
State Key Laboratory of Chemical Oncogenomics, Tsinghua Shenzhen International Graduate School, Shenzhen, China
6 shared publicationsYuyang Jiang
6 shared publications- Chunmei Gao
The Ministry-Province Jointly Constructed Base for State Key Lab-Shenzhen Key Laboratory of Chemical Biology, The Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, PR China; National & Local United Engineering Lab for Personalized Anti-tumor Drugs, The Graduate School at Shenzhen, Tsinghua University, Shenzhen 518055, PR China
5 shared publications Dan Li
Department of Chemistry, Tsinghua University, Beijing 100084, PR China; State Key Laboratory of Chemical Oncogenomics, Key Laboratory of Chemical Biology, The Graduate School at Shenzhen, Tsinghua University, Shenzhen, Guangdong 518055, PR China
5 shared publications
Latest Publications
- 29 August 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (18) , 19022-19040
Design, Synthesis, and Biological Evaluation of Quinoline-Based Hydroxamic Acid Derivatives as Dual DNMT and HDAC Inhibitors with Potent Anti-Breast Cancer Activity
Both DNA methyltransferases (DNMTs) and histone deacetylases (HDACs) play complementary roles in epigenetic regulation, and their simultaneous inhibition is a promising strategy for cancer therapy. Herein, we report the design, synthesis, and biological evaluation of a series of quinoline-based hydroxamic acid derivatives as dual DNMT and HDAC inhibitors. Notably, compound Y7 emerged as the most potent dual-target inhibitor, with IC50 values of 365 and 0.20 nM against DNMT1 and HDAC1, respectively. Furthermore, Y7 exhibited significantly enhanced antitumor efficacy compared with that of decitabine-SAHA combination in breast cancer cells. The results of in vivo experiments showed that Y7 markedly reduced tumor growth in both xenograft and transgenic breast cancer mouse models, presenting superior efficacy than the decitabine-SAHA combination without detectable toxicity. Altogether, these results present Y7 as a promising dual DNMT and HDAC inhibitor with the potential for further development as a therapeutic agent for breast cancer.
- 29 August 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (18) , 19022-19040
Design, Synthesis, and Biological Evaluation of Quinoline-Based Hydroxamic Acid Derivatives as Dual DNMT and HDAC Inhibitors with Potent Anti-Breast Cancer Activity
Both DNA methyltransferases (DNMTs) and histone deacetylases (HDACs) play complementary roles in epigenetic regulation, and their simultaneous inhibition is a promising strategy for cancer therapy. Herein, we report the design, synthesis, and biological evaluation of a series of quinoline-based hydroxamic acid derivatives as dual DNMT and HDAC inhibitors. Notably, compound Y7 emerged as the most potent dual-target inhibitor, with IC50 values of 365 and 0.20 nM against DNMT1 and HDAC1, respectively. Furthermore, Y7 exhibited significantly enhanced antitumor efficacy compared with that of decitabine-SAHA combination in breast cancer cells. The results of in vivo experiments showed that Y7 markedly reduced tumor growth in both xenograft and transgenic breast cancer mouse models, presenting superior efficacy than the decitabine-SAHA combination without detectable toxicity. Altogether, these results present Y7 as a promising dual DNMT and HDAC inhibitor with the potential for further development as a therapeutic agent for breast cancer.
- Open Access
- 5 January 2024
- Published by Springer Nature in Cell Death & Disease
- Vol. 15 (1) , 1-12
Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer
PARP inhibitors and HDAC inhibitors have been approved for the clinical treatment of malignancies, but acquired resistance of or limited effects on solid tumors with a single agent remain as challenges. Bioinformatics analyses and a combination of experiments had demonstrated the synergistic effects of PARP and HDAC inhibitors in triple-negative breast cancer. A series of novel dual PARP and HDAC inhibitors were rationally designed and synthesized, and these molecules exhibited high enzyme inhibition activity with excellent antitumor effects in vitro and in vivo. Mechanistically, dual PARP and HDAC inhibitors induced BRCAness to restore synthetic lethality and promoted cytosolic DNA accumulation, which further activates the cGAS–STING pathway and produces proinflammatory chemokines through type I IFN-mediated JAK–STAT pathway. Moreover, these inhibitors promoted neoantigen generation, upregulated antigen presentation genes and PD-L1, and enhanced antitumor immunity when combined with immune checkpoint blockade therapy. These results indicated that novel dual PARP and HDAC inhibitors have antitumor immunomodulatory functions in triple-negative breast cancer.
- 5 January 2024
- Published by Springer Nature in Cell Death & Disease
- Vol. 15 (1) , 1-12
Open AccessNovel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer
PARP inhibitors and HDAC inhibitors have been approved for the clinical treatment of malignancies, but acquired resistance of or limited effects on solid tumors with a single agent remain as challenges. Bioinformatics analyses and a combination of experiments had demonstrated the synergistic effects of PARP and HDAC inhibitors in triple-negative breast cancer. A series of novel dual PARP and HDAC inhibitors were rationally designed and synthesized, and these molecules exhibited high enzyme inhibition activity with excellent antitumor effects in vitro and in vivo. Mechanistically, dual PARP and HDAC inhibitors induced BRCAness to restore synthetic lethality and promoted cytosolic DNA accumulation, which further activates the cGAS–STING pathway and produces proinflammatory chemokines through type I IFN-mediated JAK–STAT pathway. Moreover, these inhibitors promoted neoantigen generation, upregulated antigen presentation genes and PD-L1, and enhanced antitumor immunity when combined with immune checkpoint blockade therapy. These results indicated that novel dual PARP and HDAC inhibitors have antitumor immunomodulatory functions in triple-negative breast cancer.
- 1 July 2020
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 30 (14) , 127225
Discovery of triazolo [1,5-a] pyridine derivatives as novel JAK1/2 inhibitors
- 1 July 2020
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 30 (14) , 127225
Discovery of triazolo [1,5-a] pyridine derivatives as novel JAK1/2 inhibitors
- 1 February 2020
- Published by Elsevier in Chinese Chemical Letters
- Vol. 31 (2) , 404-408
Design, synthesis and biological evaluation of novel phthalazinone acridine derivatives as dual PARP and Topo inhibitors for potential anticancer agents
- 1 February 2020
- Published by Elsevier in Chinese Chemical Letters
- Vol. 31 (2) , 404-408
Design, synthesis and biological evaluation of novel phthalazinone acridine derivatives as dual PARP and Topo inhibitors for potential anticancer agents
- 1 June 2019
- Published by Elsevier in Bioorganic Chemistry
- Vol. 87, 200-208
Development of a versatile DNMT and HDAC inhibitor C02S modulating multiple cancer hallmarks for breast cancer therapy
- 1 June 2019
- Published by Elsevier in Bioorganic Chemistry
- Vol. 87, 200-208
Development of a versatile DNMT and HDAC inhibitor C02S modulating multiple cancer hallmarks for breast cancer therapy
- 1 June 2019
- Published by Elsevier in Chinese Chemical Letters
- Vol. 30 (6) , 1233-1236
Combined inhibition of HDAC and DNMT1 induces p85α/MEK-mediated cell cycle arrest by dual target inhibitor 208 in U937 cells
- 1 June 2019
- Published by Elsevier in Chinese Chemical Letters
- Vol. 30 (6) , 1233-1236
Combined inhibition of HDAC and DNMT1 induces p85α/MEK-mediated cell cycle arrest by dual target inhibitor 208 in U937 cells
- 1 January 2019
- Published by Elsevier in Chinese Chemical Letters
- Vol. 30 (1) , 243-246
Design, synthesis and biological evaluation of a novel platinum(II) complex possessing bioreductive groups for cancer therapy
- 1 January 2019
- Published by Elsevier in Chinese Chemical Letters
- Vol. 30 (1) , 243-246
Design, synthesis and biological evaluation of a novel platinum(II) complex possessing bioreductive groups for cancer therapy
- 1 November 2018
- Published by Elsevier in Tetrahedron
- Vol. 74 (44) , 6459-6464
Highly sensitive and selective “naked eye” sensing of Cu(II) by a novel acridine-based sensor both in aqueous solution and on the test kit
- 1 November 2018
- Published by Elsevier in Tetrahedron
- Vol. 74 (44) , 6459-6464
Highly sensitive and selective “naked eye” sensing of Cu(II) by a novel acridine-based sensor both in aqueous solution and on the test kit
- 1 August 2018
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 26 (14) , 3958-3966
Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors
- 1 August 2018
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 26 (14) , 3958-3966
Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors
- 1 May 2018
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 151, 237-247
Phthalimide conjugations for the degradation of oncogenic PI3K
- 1 May 2018
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 151, 237-247
Phthalimide conjugations for the degradation of oncogenic PI3K